IVPH -- INNOVIVE Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVPH -- INNOVIVE Pharmaceuticals

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (3)	8/22/2007 8:07:56 AM
From: rkrw	Read Replies (1) of 117

Tuck, we went over this once before. :) sgx is designing a small molecule drug highly selective for the 315i mutation. This is a serious challenge and why nvs paid up for an option on it. Now on their 3rd try hopefully they can get it done. This would be combination therapy. Current target is ind 1H 2008. On 406, the trial was hard core, 2nd to 4th line failures, resistant and refractory. Most were treated at suboptimal doses as well as they dose escalated. By design 406 is trying to get the efficacy of sprycel with the tox of gleevec. Should start pivotal studies this year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next